Javier Loricera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9457246/publications.pdf

Version: 2024-02-01

430874 501196 1,305 29 18 28 citations h-index g-index papers 31 31 31 1456 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Safety of secukinumab for the treatment of active ankylosing spondylitis. Expert Opinion on Drug Safety, 2021, 20, 1-8.	2.4	5
2	Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110209.	2.7	7
3	Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary Sjögren syndrome. Rheumatology International, 2020, 40, 1259-1265.	3.0	4
4	Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 112-119.	0.8	3
5	Digestive involvement in primary Sjögren's syndrome: analysis from the Sjögrenser registry. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 110-115.	0.8	O
6	Apremilast in refractory orogenital ulcers and other manifestations of Beh $\tilde{\text{A}}$ Set's disease. A national multicentre study of 51 cases in clinical practice. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 69-75.	0.8	2
7	Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. Seminars in Arthritis and Rheumatism, 2019, 48, 720-727.	3.4	63
8	Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. American Journal of Ophthalmology, 2019, 200, 85-94.	3.3	81
9	Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Seminars in Arthritis and Rheumatism, 2019, 49, 126-135.	3.4	66
10	Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study. Rheumatology, 2018, 57, 856-864.	1.9	88
11	A closer look at skin involvement in vasculitis. Nature Reviews Rheumatology, 2018, 14, 186-187.	8.0	5
12	Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Seminars in Arthritis and Rheumatism, 2018, 48, 22-27.	3.4	123
13	Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease. Ophthalmology, 2018, 125, 1444-1451.	5.2	50
14	18 F-FDG PET/CT in the follow-up of large-vessel vasculitis: A study of 37 consecutive patients. Seminars in Arthritis and Rheumatism, 2018, 47, 530-537.	3.4	45
15	Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 171.	0.8	3
16	Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review. Ocular Immunology and Inflammation, 2017, 25, 609-614.	1.8	33
17	Anti–Interleukinâ€6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis–Associated Uveitis Refractory to Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of Twentyâ€Five Patients. Arthritis and Rheumatology, 2017, 69, 668-675.	5.6	129
18	Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Seminars in Arthritis and Rheumatism, 2016, 46, 95-101.	3.4	77

#	Article	IF	CITATIONS
19	Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clinical and Experimental Rheumatology, 2016, 34, S44-53.	0.8	32
20	Histopathologic differences between cutaneous vasculitis associated with severe bacterial infection and cutaneous vasculitis secondary to other causes: study of 52 patients. Clinical and Experimental Rheumatology, 2016, 34, S93-7.	0.8	1
21	The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to BehA§et's disease: results of a multicentre open-label study. Clinical and Experimental Rheumatology, 2016, 34, S34-S40.	0.8	10
22	Biologic therapy in ANCA-negative vasculitis. International Immunopharmacology, 2015, 27, 213-219.	3.8	15
23	Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. Seminars in Arthritis and Rheumatism, 2015, 44, 717-723.	3.4	114
24	Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. Rheumatology, 2015, 54, 77-82.	1.9	42
25	Urticarial Vasculitis in Northern Spain. Medicine (United States), 2014, 93, 53-60.	1.0	46
26	Drug-associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center. Journal of Rheumatology, 2014, 41, 2201-2207.	2.0	32
27	Henoch-Schönlein Purpura in Northern Spain. Medicine (United States), 2014, 93, 106-113.	1.0	117
28	Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clinical and Experimental Rheumatology, 2014, 32, S79-89.	0.8	55
29	The Spectrum of Paraneoplastic Cutaneous Vasculitis in a Defined Population. Medicine (United) Tj ETQq $1\ 1\ 0.78$	34314 rgB	T <u> O</u> verlock 1